Positioning your company for merger and acquisition to obtain the best deal value

In Partnering & Investment by valerie limLeave a Comment

Learn how to maximise deal value through good positioning of your company for merger and acquisition from Mr Ken Araki, Senior Director, Takeda Pharmaceutical, Japan. He will be speaking at Pharma Partnering & Investment World Asia 2012 on the 20th of March. This is part of a series of conferences at the 5th Annual BioPharma Asia Convention 2012.

Mr Ken Araki has a responsibility to initiate and manage global corporate-wide strategic projects to support Takeda's Senior Management team including President & CEO at the company. His team is also heavily involved in building up company's strategic direction based on input from internal and external while cooperating with other colleagues in charge of corporate controller function at Corporate Strategic Planning. He has currently another role to head Corporate Development team at Global Business Development group. Under his this role, he recently successfully executed the acquisition of Nycomed and involves in integrate into Takeda's organization, Prior to Ken's current role which was assigned in October 2009, he has been responsible for a Head of M&A. During his tenure, he successfully executed the acquisition of Millennium Pharmaceuticals and its integration into Takeda organization.

Prior to joining Takeda in May 2006, he belongs to Investment Banking team with Nomura Securities, a largest firm in Japan. During his tenure, he acted a financial advisor to help to create Daiichi-Sankyo, one of the largest Japanese pharmaceutical companies. He had experienced to analyze pharmaceutical and biotech industry globally over ten years at Nomura as a sell-side analyst. Especially he played a central role on Global Pharmaceutical Equity Research at New York between 1996 and 2004. Ken had a Bachelor of Law degree from Kyushu University in 1989.

Mr Ken Araki will be presenting on the following subject:

Positioning your company for merger and acquisition to obtain the best deal value
1. Describing the company's strategy in the most attractive manner to attract potential partners
2. Anticipating key issues in a deal and accounting for them early during strategic planning
3. Defining interim and long term objectives as well as goals and target dates for the company

If you are keen to find out more, join us at BioPharma Asia Convention 2012 to gain valuable insights from more than 200 experts. Contact us now for more details!

Leave a Comment

Current ye@r *